HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marco De Martino Selected Research

HMGA Proteins

2/2022Critical role of the high mobility group A proteins in hematological malignancies.
2/2021Interplay between HMGA and TP53 in cell cycle control along tumor progression.
1/2021HMGA1 induces EZH2 overexpression in human B-cell lymphomas.
4/2020HMGA1-Regulating microRNAs Let-7a and miR-26a are Downregulated in Human Seminomas.
9/2019Emerging Role of USP8, HMGA, and Non-Coding RNAs in Pituitary Tumorigenesis.
1/2019HMGA and Cancer: A Review on Patent Literatures.
1/2019Overexpression of HMGA1 Figures as a Potential Prognostic Factor in Endometrioid Endometrial Carcinoma (EEC).
5/2016HMGA2 overexpression plays a critical role in the progression of esophageal squamous carcinoma.
1/2015HMGA1-pseudogene expression is induced in human pituitary tumors.
9/2014HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marco De Martino Research Topics

Disease

24Neoplasms (Cancer)
06/2022 - 01/2014
7Carcinogenesis
02/2021 - 10/2016
4Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
01/2021 - 01/2019
2Thyroid Neoplasms (Thyroid Cancer)
06/2022 - 01/2017
2B-Cell Lymphoma (Lymphoma, B Cell)
02/2022 - 01/2020
2Seminoma
04/2020 - 01/2019
2Pituitary Neoplasms (Pituitary Adenoma)
09/2019 - 01/2015
1Carcinoma (Carcinomatosis)
06/2022
1Papillary Carcinoma
06/2022
1Hematologic Neoplasms (Hematological Malignancy)
02/2022
1Neuroendocrine Tumors (Neuroendocrine Tumor)
01/2022
1Genomic Instability
02/2021
1Testicular Neoplasms (Testicular Cancer)
01/2021
1Glioblastoma (Glioblastoma Multiforme)
01/2021
1Neoplasm Metastasis (Metastasis)
01/2021
1Low Cardiac Output
10/2020
1Peripheral Arterial Disease
10/2020
1Immediate Hypersensitivity
10/2019
1Neoplastic Cell Transformation
01/2019
1Brain Neoplasms (Brain Tumor)
01/2019
1Testicular Germ Cell Tumor
01/2019
1Papillary Thyroid Cancer
01/2017
1Down Syndrome (Down's Syndrome)
01/2017

Drug/Important Bio-Agent (IBA)

13Proteins (Proteins, Gene)FDA Link
06/2022 - 09/2014
12MicroRNAs (MicroRNA)IBA
01/2021 - 01/2014
10HMGA ProteinsIBA
02/2022 - 09/2014
5Messenger RNA (mRNA)IBA
04/2020 - 01/2015
2Biological ProductsIBA
02/2021 - 01/2021
2RNA (Ribonucleic Acid)IBA
01/2021 - 01/2020
2Transcription Factors (Transcription Factor)IBA
01/2019 - 03/2018
2Competitive Endogenous RNAIBA
11/2016 - 01/2015
1RacivirIBA
06/2022
1Long Noncoding RNAIBA
06/2021
1DNA (Deoxyribonucleic Acid)IBA
02/2021
1Biomarkers (Surrogate Marker)IBA
01/2021
1Temozolomide (Temodar)FDA LinkGeneric
01/2021
1Protein SIBA
04/2020
1CytokinesIBA
10/2019
1Immunoglobulin E (IgE)IBA
10/2019
1Ubiquitin-Specific ProteasesIBA
09/2019
1Brentuximab VedotinIBA
01/2019
1NivolumabIBA
01/2019
1Monoclonal AntibodiesIBA
01/2019
1Immune Checkpoint InhibitorsIBA
01/2019
1pembrolizumabIBA
01/2019
1Nucleotide AptamersIBA
01/2019
1claudin 6IBA
01/2019
1Aurora KinasesIBA
01/2019
1Forkhead Box Protein M1IBA
03/2018
1Cyclin B1IBA
10/2016
1Growth Hormone (Somatotropin)IBA
01/2015

Therapy/Procedure

3Therapeutics
01/2019 - 01/2019
1Investigational Therapies (Experimental Therapy)
02/2022
1Coronary Artery Bypass (Coronary Artery Bypass Surgery)
10/2020
1Cardiopulmonary Bypass (Heart-Lung Bypass)
10/2020